On Wednesday, DryShips Inc. (NASDAQ:DRYS)’s shares inclined 7.48% to $0.556.
DryShips Inc. (DRYS) declared the results of its 2015 Annual General Meeting of Shareholders.
The following proposals were approved and adopted at the Meeting:
- The election of Mr. George Xiradakis as Class B Director of the Company to serve until the 2018 Annual General Meeting of Shareholders; and
- the approval of the appointment of Ernst & Young (Hellas) Certified Auditors Accountants S.A., as the Company’s independent auditors for the fiscal year ending December 31, 2015.
DryShips Inc. provides ocean transportation services for drybulk and petroleum cargoes, and offshore deepwater drilling services. The company operates through Drybulk, Tanker, and Drilling segments. The Drybulk segment provides drybulk commodities transportation services for the steel, electric utility, construction, and agri-food industries. The Drilling segment offers ultra deep water drilling services.
The Medicines Company (NASDAQ:MDCO)’s shares dropped -7.56% to $30.95.
The Medicines Company (MDCO) recently declared its financial results for the second quarter and first half of 2015.
Second-Quarter 2015 Financial Summary
Worldwide net revenue was $90.5 million for the second quarter of 2015 contrast to $183.8 million in the second quarter of 2014. Worldwide Angiomax®/Angiox® (bivalirudin) revenue was $65.6 million in the second quarter of 2015 contrast to $163.1 million in the second quarter of 2014, with revenue in the United States decreasing to $60.5 million in the second quarter of 2015 from $152.2 million in the second quarter of 2014. Recothrom®, Thrombin topical (Recombinant) sales were $15.9 million contrast to $16.3 million in the second quarter of 2014. Other products counting Cleviprex® (clevidipine), Argatroban for Injection, 50 mg per mL, Minocin® (minocycline) for injection, Orbactiv® (oritavancin) and PreveLeakTM Surgical Sealant recorded sales of $9.0 million during second quarter of 2015 contrast to $4.4 million in the second quarter of 2014. Not taking into account Angiomax, the company recorded 20% higher net revenue during the second quarter of 2015 contrast to the second quarter of 2014.
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, in addition to acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases.
At the end of Wednesday’s trade, NetApp Inc. (NASDAQ:NTAP)‘s shares surged 0.03% to $30.96.
NetApp ( NTAP) experts will share the latest innovations in flash and enterprise application integration technology at the Flash Memory Summit 2015, August 11-13, at the Santa Clara Convention Center, Santa Clara, CA.
The NetApp team will deliver perspectives on flash trends and industry issues at six summit speaking sessions. In booth 511, attendees can learn more about NetApp’s unique ability to assist customers manage enterprise data from flash to disk cloud and the company’s newest all-flash offering, the NetApp® AFF8000 series.
NetApp, Inc. provides software, systems, and services to manage and store computer data worldwide. It offers Data ONTAP storage operating system that delivers integrated data protection, comprehensive data administration, and built-in software for virtualized, shared infrastructures, cloud computing, and mixed workload business applications; E-Series storage systems for storage area network workloads (SAN); all-flash arrays that deliver input/output operations per second and ultralow latency to drive speed, responsiveness, and value from the applications that control key business operations; and hybrid arrays for mainstream business applications.
Total System Services, Inc. (NYSE:TSS), ended its Wednesday’s trading session with 4.58% gain, and closed at $46.83.
TSYS (TSS) declared that it has signed a long-term renewal with U.S. Bank. As part of the agreement, TSYS will continue to support the bank’s commercial card payment services in the United States, Europe and Canada, and will also support their acquiring business.
Total System Services, Inc. provides electronic payment processing services to banks and other financial institutions in the United States, Europe, Canada, Mexico, and internationally. It operates through four segments: North America Services, International Services, Merchant Services, and NetSpend. The company offers account processing and output services, counting processing the card application, initiating service for the cardholder, processing card transaction for the issuing retailer or financial institution, and accumulating the account’s transactions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
